IBDEI1XG ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30786,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney
 ;;^UTILITY(U,$J,358.3,30786,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,30786,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,30787,0)
 ;;=I13.10^^123^1587^9
 ;;^UTILITY(U,$J,358.3,30787,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30787,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney
 ;;^UTILITY(U,$J,358.3,30787,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,30787,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,30788,0)
 ;;=I15.1^^123^1587^11
 ;;^UTILITY(U,$J,358.3,30788,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30788,1,3,0)
 ;;=3^Hypertension Secondary to Oth Renal Disorders
 ;;^UTILITY(U,$J,358.3,30788,1,4,0)
 ;;=4^I15.1
 ;;^UTILITY(U,$J,358.3,30788,2)
 ;;=^5007072
 ;;^UTILITY(U,$J,358.3,30789,0)
 ;;=I15.2^^123^1587^10
 ;;^UTILITY(U,$J,358.3,30789,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30789,1,3,0)
 ;;=3^Hypertension Secondary to Endocrine Disorders
 ;;^UTILITY(U,$J,358.3,30789,1,4,0)
 ;;=4^I15.2
 ;;^UTILITY(U,$J,358.3,30789,2)
 ;;=^5007073
 ;;^UTILITY(U,$J,358.3,30790,0)
 ;;=I50.1^^123^1587^16
 ;;^UTILITY(U,$J,358.3,30790,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30790,1,3,0)
 ;;=3^Left Ventricular Failure
 ;;^UTILITY(U,$J,358.3,30790,1,4,0)
 ;;=4^I50.1
 ;;^UTILITY(U,$J,358.3,30790,2)
 ;;=^5007238
 ;;^UTILITY(U,$J,358.3,30791,0)
 ;;=E26.09^^123^1587^17
 ;;^UTILITY(U,$J,358.3,30791,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30791,1,3,0)
 ;;=3^Primary Hyperaldosteronism,Other
 ;;^UTILITY(U,$J,358.3,30791,1,4,0)
 ;;=4^E26.09
 ;;^UTILITY(U,$J,358.3,30791,2)
 ;;=^5002735
 ;;^UTILITY(U,$J,358.3,30792,0)
 ;;=I15.8^^123^1587^18
 ;;^UTILITY(U,$J,358.3,30792,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30792,1,3,0)
 ;;=3^Secondary Hypertension,Other
 ;;^UTILITY(U,$J,358.3,30792,1,4,0)
 ;;=4^I15.8
 ;;^UTILITY(U,$J,358.3,30792,2)
 ;;=^5007074
 ;;^UTILITY(U,$J,358.3,30793,0)
 ;;=E27.5^^123^1587^1
 ;;^UTILITY(U,$J,358.3,30793,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30793,1,3,0)
 ;;=3^Adrenomedullary Hyperfunction
 ;;^UTILITY(U,$J,358.3,30793,1,4,0)
 ;;=4^E27.5
 ;;^UTILITY(U,$J,358.3,30793,2)
 ;;=^5002744
 ;;^UTILITY(U,$J,358.3,30794,0)
 ;;=E26.01^^123^1587^4
 ;;^UTILITY(U,$J,358.3,30794,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30794,1,3,0)
 ;;=3^Conn's Syndrome
 ;;^UTILITY(U,$J,358.3,30794,1,4,0)
 ;;=4^E26.01
 ;;^UTILITY(U,$J,358.3,30794,2)
 ;;=^329905
 ;;^UTILITY(U,$J,358.3,30795,0)
 ;;=I15.9^^123^1587^19
 ;;^UTILITY(U,$J,358.3,30795,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30795,1,3,0)
 ;;=3^Secondary Hypertension,Unspec
 ;;^UTILITY(U,$J,358.3,30795,1,4,0)
 ;;=4^I15.9
 ;;^UTILITY(U,$J,358.3,30795,2)
 ;;=^5007075
 ;;^UTILITY(U,$J,358.3,30796,0)
 ;;=B20.^^123^1588^3
 ;;^UTILITY(U,$J,358.3,30796,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30796,1,3,0)
 ;;=3^HIV Disease
 ;;^UTILITY(U,$J,358.3,30796,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,30796,2)
 ;;=^5000555
 ;;^UTILITY(U,$J,358.3,30797,0)
 ;;=J18.9^^123^1588^6
 ;;^UTILITY(U,$J,358.3,30797,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30797,1,3,0)
 ;;=3^Pneumonia,Unspec Organism
 ;;^UTILITY(U,$J,358.3,30797,1,4,0)
 ;;=4^J18.9
 ;;^UTILITY(U,$J,358.3,30797,2)
 ;;=^95632
 ;;^UTILITY(U,$J,358.3,30798,0)
 ;;=J10.1^^123^1588^1
 ;;^UTILITY(U,$J,358.3,30798,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30798,1,3,0)
 ;;=3^Flu w/ Respiratory Manifestations
